Michelle Morrow

3.8k citations

34 papers · 2.0k indexed · 1 hit paper · h-index 14

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in ⓘ

Oncology 22
- Cancer Immunotherapy and Biomarkers 16
- CAR-T cell therapy research 5
Immunology 18
- Immunotherapy and Immune Responses 14
- Immune Cell Function and Interaction 5
- T-cell and B-cell Immunology 3

Co-authors: Ross Stewart (8 shared papers)Robert W. Wilkinson (7 shared papers)Simon J. Dovedi (6 shared papers)Jamie Honeychurch (5 shared papers)Edmund Poon (7 shared papers)Tim Illidge (5 shared papers)Eleanor J. Cheadle (2 shared papers)Grazyna Lipowska‐Bhalla (3 shared papers)
Journals: Cancer Research (11 papers)Clinical Cancer Research (2 papers)Journal for ImmunoTherapy of Cancer (2 papers)Blood (2 papers)Nutrients (1 paper)
Partner nations: United Kingdom United States Canada

In The Last Decade

Michelle Morrow

32 papers receiving 2.0k citations

Hit Papers

align trajectories log scale

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade 2014 · 974 citations

Peers

Countries citing papers authored by Michelle Morrow

Since Specialization

Citations

This map shows the geographic impact of Michelle Morrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Morrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Morrow more than expected).

Fields of papers citing papers by Michelle Morrow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Morrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Morrow. The network helps show where Michelle Morrow may publish in the future.

Co-authors

The 25 scholars most cited alongside Michelle Morrow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michelle Morrow Line = papers co-authored together Michelle Morrow links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade Cancer Research ·Simon J. Dovedi, Amy L. Adlard, Grazyna Lipowska‐Bhalla, Conor McKenna, Sherrie Jones, Eleanor J. Cheadle, Ian J. Stratford, Edmund Poon, Michelle Morrow, Ross Stewart, Hazel Jones, Robert W. Wilkinson, Jamie Honeychurch, Tim Illidge Hit paper breakdown →	2014	974
2	Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade Clinical Cancer Research ·Simon J. Dovedi, Eleanor J. Cheadle, Amy L. Popple, Edmund Poon, Michelle Morrow, Ross Stewart, Erik Yusko, Catherine Sanders, Marissa Vignali, Ryan Emerson, Harlan Robins, Robert W. Wilkinson, Jamie Honeychurch, Tim Illidge	2017	263
3	Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53 Leukemia ·N. E. Gefen, Vera Binder, Markéta Žaliová, Yvonne Linka, Michelle Morrow, Astrid Novosel, Liat Edry, Libi Hertzberg, Noam Shomron, Owen Williams, Jan Trka, Arndt Borkhardt, Shai Izraeli	2009	92
4	ERG Is a Megakaryocytic Oncogene Cancer Research ·Samira Salek‐Ardakani, Gil Smooha, Jasper de Boer, Neil J. Sebire, Michelle Morrow, Liat Rainis, Sandy Lee, Owen Williams, Shai Izraeli, Hugh J.M. Brady	2009	84
5	FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity Clinical Cancer Research ·Matthew Kraman, Mustapha Faroudi, Natalie L. Allen, Katarzyna Kmiecik, Daniel Gliddon, Claire J. Seal, Alexander Koers, Mateusz Wydro, Sarah Batey, Julia Winnewisser, Lesley Young, Mihriban Tuna, Jacqueline Doody, Michelle Morrow, Neil Brewis	2020	82
6	TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity Blood ·Michelle Morrow, Sarah J. Horton, Dimitris Kioussis, Hugh J.M. Brady, Owen Williams	2004	76
7	Mild and efficient ligand-free copper-catalyzed condensation for the synthesis of quinazolines Tetrahedron Letters ·Vouy Linh Truong, Michelle Morrow	2009	70
8	Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model Oncotarget ·Nadia Luheshi, Jane Coates-Ulrichsen, James A. Harper, Stefanie Mullins, Michal Sulikowski, Philip Martin, Lee R. Brown, Arthur Lewis, Gareth Davies, Michelle Morrow, Robert W. Wilkinson	2016	67
9	Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma OncoImmunology ·Anna I. Hooijkaas, Jules Gadiot, Michelle Morrow, Ross Stewart, Ton N. Schumacher, Christian U. Blank	2012	60
10	Continuous MLL-ENL Expression Is Necessary to Establish a “Hox Code” and Maintain Immortalization of Hematopoietic Progenitor Cells Cancer Research ·Sarah J. Horton, David G. Grier, Glenda J. McGonigle, Alexander Thompson, Michelle Morrow, Inusha De Silva, Dale Moulding, Dimitris Kioussis, Terence R.J. Lappin, Hugh J.M. Brady, Owen Williams	2005	55
11	CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement Cancer Immunology Research ·Miguel Gaspar, John Pravin, Leonor Nunes Rodrigues, Sandra Uhlenbroich, Katy L. Everett, Francisca Wollerton, Michelle Morrow, Mihriban Tuna, Neil Brewis	2020	43
12	CBFβ is critical for AML1-ETO and TEL-AML1 activity Blood ·Liya Roudaia, Matthew D. Cheney, Ekaterina Manuylova, Wei Chen, Michelle Morrow, Sang‐Ho Park, Chung-Tsai Lee, Prabhjot Kaur, Owen Williams, John H. Bushweller, Nancy A. Speck	2009	40
13	TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL Oncogene ·Michelle Morrow, A. Samanta, D Kioussis, Hugh J.M. Brady, Owen Williams	2007	31
14	Abstract 2719: Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses Cancer Research ·Matthew Kraman, Natalie Fosh, Katarzyna Kmiecik, Katy L. Everett, Carlo Zimarino, Mustapha Faroudi, Mateusz Wydro, Alexander Koers, Lesley Young, Daniel Gliddon, Michelle Morrow, Jacqueline Doody, Mihriban Tuna, Neil Brewis	2018	13
15	395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy Regular and Young Investigator Award Abstracts ·Timothy A. Yap, Deborah Wong, Siwen Hu‐Lieskovan, Kyriakos P. Papadopoulos, Michelle Morrow, Urszula Grabowska, Daniel Gliddon, Josefin-Beate Holz, Patricia LoRusso	2020	11
16	Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments Frontiers in Immunology ·Suzanne I. Sitnikova, Jennifer A. Walker, Laura B. Prickett, Michelle Morrow, Viia Valge-Archer, Matthew J. Robinson, Robert W. Wilkinson, Simon J. Dovedi	2023	9
17	Radiation Therapy Induces an Adaptive Upregulation of PD-L1 on Tumor Cells Which May Limit the Efficacy of the Anti-Tumor Immune Response But Can Be Circumvented by Anti-PD-L1 International Journal of Radiation OncologyBiologyPhysics ·Tim Illidge, Grazyna Lipowska‐Bhalla, Eleanor Cheadle, Jamie Honeychurch, Edmund Poon, Michelle Morrow, Ross Stewart, R. Wilkinson, Simon J. Dovedi	2014	8
18	Abstract LB-158: MEDI4736: Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development Cancer Research ·Ross Stewart, Michelle Morrow, Matthieu Chodorge, Danielle Marcus, Melanie Boyle, Kathy Mulgrew, Scott A. Hammond, Suping Wang, Marat Alimzhanov, Paul D. Robbins, Karen Lanning, Vahe Bedian, Matthew McCourt, Mathew M. S. Lo	2011	7
19	Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report Journal for ImmunoTherapy of Cancer ·Maxwell Kroloff, Josefin-Beate Holz, Omer Stern, Christopher J. Shepherd, Michelle Morrow, Louis Kayitalire, Deborah Jean Lee Wong	2022	6
20	Preclinical modelling of immune checkpoint blockade (P2012) The Journal of Immunology ·Ross Stewart, Stefanie Mullins, Amanda Watkins, Michelle Morrow, Richard C.A. Sainson, Paul F. Robbins, Theresa La Vallee, Robert W. Wilkinson	2013	6

About Michelle Morrow

Michelle Morrow is a scholar working on Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Hematology, having authored 34 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (16 papers), Immunotherapy and Immune Responses (14 papers), Acute Myeloid Leukemia Research (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), CAR-T cell therapy research (5 papers), Immune Cell Function and Interaction (5 papers), Acute Lymphoblastic Leukemia research (3 papers) and T-cell and B-cell Immunology (3 papers). The work is most often cited by research in Oncology (1.3k citations), Immunology (725 citations), Hematology (209 citations), Pulmonary and Respiratory Medicine (466 citations) and Cancer Research (158 citations). Michelle Morrow has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Ross Stewart, Robert W. Wilkinson, Simon J. Dovedi, Jamie Honeychurch, Edmund Poon, Tim Illidge, Eleanor J. Cheadle, Grazyna Lipowska‐Bhalla, Hazel Jones and Amy L. Adlard. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Blood and Nutrients.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact